Every material Form 8-K CVS Health filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CVS Health increased its board from 12 to 16 members on November 17, 2024, appointing Leslie Norwalk, Larry Robbins, Guy Sansone and Doug Shulman, after discussions with activist investor Glenview Capital Management. The company also entered a confidentiality agreement with Glenview that includes customary standstill and non-disparagement terms, and the filing describes compensation changes for two senior executives.
Board expanded from 12 to 16 members; Norwalk, Robbins, Sansone and Shulman appointed November 17, 2024
Company agreed to nominate all four for election at the 2025 annual meeting of stockholders
Glenview standstill restrictions remain in effect until 30 days before the stockholder nomination window for the 2026 annual meeting
Premium-priced stock options with grant date values of $12,000,000 for CEO J. David Joyner and $6,000,000 for Prem S. Shah, granted November 30, 2024
CVS Health appointed Prem S. Shah as a newly created Executive Vice President and Group President, responsible for operational performance across CVS Caremark, CVS Pharmacy and Health Care Delivery, including Oak Street Health and Signify Health. It also named Steven H. Nelson as Executive Vice President and President of Aetna, both effective November 6, 2024, with both reporting to CEO David Joyner. The filing describes leadership changes only and includes no financial results or guidance.
Prem S. Shah, age 44, appointed Executive Vice President and Group President, a newly created role, effective November 6, 2024.
Shah previously served as Executive Vice President and Chief Pharmacy Officer and President of Pharmacy & Consumer Wellness since January 2023.
Steven H. Nelson appointed Executive Vice President and President of Aetna; he was most recently CEO of ChenMed and a former CEO of UnitedHealthcare.
The press release is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed for Section 18 purposes.
CVS Health reported third quarter 2024 results for the three months ended September 30, 2024. Total revenues rose 6.3% to $95.4 billion, but GAAP diluted EPS fell to $0.07 from $1.75 and Adjusted EPS fell to $1.09 from $2.21, mainly due to a decline in the Health Care Benefits segment, which recorded about $1.1 billion of premium deficiency reserves. The company expects these reserves to be substantially released in the fourth quarter of 2024.
Total revenues rose 6.3% to $95.4 billion; Health Care Benefits recorded an adjusted operating loss of $924 million versus adjusted operating income of $1.5 billion a year earlier.
GAAP diluted EPS was $0.07 versus $1.75 a year earlier; Adjusted EPS was $1.09 versus $2.21.
Restructuring charges of approximately $1.2 billion were recorded, including a $607 million store impairment tied to retail pharmacy stores to be closed in 2025.
Premium deficiency reserves of approximately $1.1 billion are expected to be substantially released during the fourth quarter of 2024.
CVS Health appointed David Joyner as President and Chief Executive Officer effective October 17, 2024, replacing Karen Lynch, who also left the Board, and named Roger Farah Executive Chairman. The company also gave preliminary third quarter 2024 guidance of $0.03 to $0.08 GAAP diluted EPS and $1.05 to $1.10 Adjusted EPS, citing about $1.1 billion in premium deficiency reserve charges and about $1.2 billion in restructuring charges, and told investors not to rely on its prior guidance from August 7, 2024.
David Joyner, previously executive vice president and president of Pharmacy Services, became CEO effective October 17, 2024; Roger Farah is Executive Chairman.
Preliminary Q3 2024 GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10.
Premium deficiency reserve charges of about $1.1 billion lowered Q3 Adjusted EPS by $0.63; medical benefit ratio expected at about 95.2%.
Karen Lynch will provide advisory services for six months at a $375,000 monthly fee; her non-compete extends to 30 months. Q3 earnings call is scheduled for November 6, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CVS Health filing is on SEC EDGAR ↗. 8-K briefs of other companies →